Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction

Shilin Xu,Angelo Aguilar,Tianfeng Xu,Ke Zheng,Liyue Huang,Jeanne Stuckey,Krishnapriya Chinnaswamy,Denzil Bernard,Ester Fernandez-Salas,Liu,Mi Wang,Donna McEachern,Sally Przybranowski,Caroline Foster,Shaomeng Wang
DOI: https://doi.org/10.1002/anie.201711828
2018-01-01
Angewandte Chemie
Abstract:The structure-based design of M-525 as the first-in-class, highly potent, irreversible small-molecule inhibitor of the menin-MLL interaction is presented. M-525 targets cellular menin protein at sub-nanomolar concentrations and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL-regulated gene expression in MLL leukemia cells. M-525 demonstrates high cellular specificity over non-MLL leukemia cells and is more than 30 times more potent than its corresponding reversible inhibitors. Mass spectrometric analysis and co-crystal structure of M-525 in complex with menin firmly establish its mode of action. A single administration of M-525 effectively suppresses MLL-regulated gene expression in tumor tissue. An efficient procedure was developed to synthesize M-525. This study demonstrates that irreversible inhibition of menin may be a promising therapeutic strategy for MLL leukemia.
What problem does this paper attempt to address?